Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 21:14:1338754.
doi: 10.3389/fonc.2024.1338754. eCollection 2024.

Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data

Stephen Morrell  1 , David Roder  2 , David Currow  3 , Alexander Engel  4   5 , Elizabeth Hovey  6   7 , Craig R Lewis  6   7 , Winston Liauw  7   8 , Jarad M Martin  9   10   11 , Manish Patel  12   13 , Stephen R Thompson  7   14 , Tracey O'Brien  15
Affiliations

Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data

Stephen Morrell et al. Front Oncol. .

Abstract

Introduction: Population cancer registries record primary cancer incidence, mortality and survival for whole populations, but not more timely outcomes such as cancer recurrence, secondary cancers or other complications that disrupt event-free survival. Nonetheless, indirect evidence may be inferred from treatment data to provide indicators of recurrence and like events, which can facilitate earlier assessment of care outcomes. The present study aims to infer such evidence by applying algorithms to linked cancer registry and treatment data obtained from hospitals and universal health insurance claims applicable to the New South Wales (NSW) population of Australia.

Materials and methods: Primary invasive cancers from the NSW Cancer Registry (NSWCR), diagnosed in 2001-2018 with localized or regionalized summary stage, were linked to treatment data for five common Australian cancers: breast, colon/rectum, lung, prostate, and skin (melanomas). Clinicians specializing in each cancer type provided guidance on expected treatment pathways and departures to indicate remission and subsequent recurrence or other disruptive events. A sample survey of patients and clinicians served to test initial population-wide results. Following consequent refinement of the algorithms, estimates of recurrence and like events were generated. Their plausibility was assessed by their correspondence with expected outcomes by tumor type and summary stage at diagnosis and by their associations with cancer survival.

Results: Kaplan-Meier product limit estimates indicated that 5-year cumulative probabilities of recurrence and other disruptive events were lower, and median times to these events longer, for those staged as localized rather than regionalized. For localized and regionalized cancers respectively, these were: breast - 7% (866 days) and 34% (570 days); colon/rectum - 15% (732 days) and 25% (641 days); lung - 46% (552 days) and 66% (404 days); melanoma - 11% (893 days) and 38% (611 days); and prostate - 14% (742 days) and 39% (478 days). Cases with markers for these events had poorer longer-term survival.

Conclusions: These population-wide estimates of recurrence and like events are approximations only. Absent more direct measures, they nonetheless may inform service planning by indicating population or treatment sub-groups at increased risk of recurrence and like events sooner than waiting for deaths to occur.

Keywords: breast; cancer; colorectal; lung; melanoma; prostate; recurrence and other disruptive events; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Timeline and evolution of recurrence and like event algorithm development.
Figure 2
Figure 2
Inputs to recurrence and like event algorithm development. *CAG, Clinical advisory group.
Figure 3
Figure 3
Recurrence and like event time-to-event plots by extent of disease/summary degree of spread.
Figure 4
Figure 4
Recurrence and like event time distributions by extent of disease/summary degree of spread.
Figure 5
Figure 5
Survival from cancer as cause of death, by recurrence and like event status.
See this image and copyright information in PMC

References

    1. Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. (2002) 40:IV–75–81. doi: 10.1097/00005650-200208001-00011 - DOI - PubMed
    1. Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. (2012) 104:931–40. doi: 10.1093/jnci/djs233 - DOI - PMC - PubMed
    1. Deshpande AD, Schootman M, Mayer A. Development of a claims-based algorithm to identify colorectal cancer recurrence. Ann Epidemiol. (2015) 25:297–300. doi: 10.1016/j.annepidem.2015.01.005 - DOI - PMC - PubMed
    1. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. (2014) 52:e65–73. doi: 10.1097/MLR.0b013e318277eb6f - DOI - PMC - PubMed
    1. Hassett MJ, Uno H, Cronin AM, Carroll NM, Hornbrook MC, Ritzwoller D. Detecting lung and colorectal cancer recurrence using structured clinical/administrative data to enable outcomes research and population health management. Med Care. (2017) 55:e88–98. doi: 10.1097/MLR.0000000000000404 - DOI - PMC - PubMed

LinkOut - more resources